{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:39Z","timestamp":1783908519830,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Self-administered calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are essential therapies, but their safe use depends on adequate patient training. This study examined temporal shifts in the adverse event (AE) reporting profile for CGRP mAbs during and after the COVID-19 pandemic. We conducted a retrospective disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated for the CGRP mAb class across three cohorts: pre-pandemic (2019), pandemic (April 2020\u2013April 2023), and post-pandemic (July 2023\u2013June 2025). Significant changes were defined by non-overlapping 95% CIs. The analysis identified two divergent trends in signals of disproportionate reporting (SDR). There was a significant increase in device-related and use-error AEs, including \u201cdrug dose omission by device\u201d (ROR increased from 10.65 to 37.67) and \u201caccidental underdose\u201d (ROR from 0.29 to 16.80). Notably, the SDR for \u201cwrong technique in product usage process\u201d showed continuous intensification across all three periods. Conversely, there was a sustained and significant decrease in reporting of well-established clinical AEs, most notably for \u201cmedication overuse headache\u201d (ROR dropped from 56.92 to 2.91) and \u201cconstipation\u201d (ROR from 9.86 to 1.61). Reporting patterns shifted dynamically during the pandemic. The surge in use errors suggests vulnerabilities in patient support for self-administered therapies when in-person care is limited, highlighting a critical need for pharmacist intervention and remote education. The concurrent decline in known clinical AEs may indicate shifting reporting priorities. These findings underscore the importance of contextualizing pharmacovigilance data within public health events and warrant further investigation.<\/jats:p>","DOI":"10.1007\/s00210-026-05223-x","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:50:18Z","timestamp":1773978618000},"page":"14543-14552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent rise in device-related errors for CGRP monoclonal antibodies: impact of the COVID-19 pandemic and post-pandemic implications"],"prefix":"10.1007","volume":"399","author":[{"given":"Martina","family":"Giacon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-1121","authenticated-orcid":false,"given":"Salvatore","family":"Terrazzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"5223_CR1","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1007\/s11606-022-07827-4","volume":"37","author":"CA Berry","year":"2022","unstructured":"Berry CA, Kwok L, Massar R et al (2022) Patients\u2019 perspectives on the shift to telemedicine in primary and behavioral health care during the COVID-19 pandemic. J Gen Intern Med 37:4248\u20134256. https:\/\/doi.org\/10.1007\/s11606-022-07827-4","journal-title":"J Gen Intern Med"},{"key":"5223_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.anai.2021.12.013","volume":"129","author":"AG Burrows","year":"2022","unstructured":"Burrows AG, Ellis AK (2022) Psychological impacts of coronavirus disease 2019 on people with asthma, allergic rhinitis, and food allergy. Ann Allergy Asthma Immunol 129:52\u201361. https:\/\/doi.org\/10.1016\/j.anai.2021.12.013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"5223_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19:922\u2013930. https:\/\/doi.org\/10.1007\/s13311-022-01230-x","journal-title":"Neurotherapeutics"},{"key":"5223_CR4","unstructured":"Council for International Organizations of Medical Sciences (CIOMS) (2010) Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. CIOMS, Geneva: CIOMS. Available at https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf.\u00a0Accessed 5 Dec 2025"},{"key":"5223_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo PM, Sartori D, Tuccori M et al (2024) Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul 3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057","journal-title":"Front Drug Saf Regul"},{"key":"5223_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","volume":"23","author":"P de Boissieu","year":"2014","unstructured":"de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Dram\u00e9 M, Trenque T (2014) Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf 23:989\u2013992. https:\/\/doi.org\/10.1002\/pds.3622","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5223_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther 14:297\u2013315. https:\/\/doi.org\/10.1007\/s40122-024-00690-7","journal-title":"Pain Ther"},{"key":"5223_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/pds.5217","volume":"30","author":"M D\u00f6rks","year":"2021","unstructured":"D\u00f6rks M, Jobski K, Hoffmann F, Douros A (2021) Global COVID-19 pandemic and reporting behavior - an analysis of the Food and Drug Administration adverse events reporting system. Pharmacoepidemiol Drug Saf 30:707\u2013715. https:\/\/doi.org\/10.1002\/pds.5217","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"5223_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"5223_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","unstructured":"GBD 2021 Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23:344\u2013381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"5223_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.pharma.2021.02.003","volume":"79","author":"M Gras","year":"2021","unstructured":"Gras M, Gras-Champel V, Moragny J et al (2021) Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication. Ann Pharm Fr 79:522\u2013529. https:\/\/doi.org\/10.1016\/j.pharma.2021.02.003","journal-title":"Ann Pharm Fr"},{"key":"5223_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01152-2","volume":"7","author":"E Hatef","year":"2024","unstructured":"Hatef E, Wilson RF, Zhang A et al (2024) Effectiveness of telehealth versus in-person care during the COVID-19 pandemic: a systematic review. NPJ Digit Med 7:157. https:\/\/doi.org\/10.1038\/s41746-024-01152-2","journal-title":"NPJ Digit Med"},{"issue":"2","key":"5223_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clinthera.2020.12.008","volume":"43","author":"M Hauben","year":"2021","unstructured":"Hauben M, Hung E (2021) Effects of the COVID-19 pandemic on spontaneous reporting: global and national time-series analyses. Clin Ther 43(2):360-368.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.008","journal-title":"Clin Ther"},{"key":"5223_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions\u202f: a systematic review. Drug Saf 29:385\u2013396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"key":"5223_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM (2014) The weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 37:283\u2013294. https:\/\/doi.org\/10.1007\/s40264-014-0150-2","journal-title":"Drug Saf"},{"key":"5223_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.820006","volume":"12","author":"P Holzer","year":"2022","unstructured":"Holzer P, Holzer-Petsche U (2022) Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide\u2019s motor-stimulating and prosecretory function in the intestine. Front Physiol 12:820006. https:\/\/doi.org\/10.3389\/fphys.2021.820006","journal-title":"Front Physiol"},{"key":"5223_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/20503121231170726","volume":"11","author":"O Hrytsenko","year":"2023","unstructured":"Hrytsenko O, Kopchak O, Kozyk M, Strubchevska K (2023) The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med 11:20503121231170726. https:\/\/doi.org\/10.1177\/20503121231170726","journal-title":"SAGE Open Med"},{"key":"5223_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2147\/PPA.S248584","volume":"14","author":"J Mead","year":"2020","unstructured":"Mead J, Dammerman R, Rasmussen S (2020) Patient reported ease-of-use with a disposable autoinjector in individuals with migraine. Patient Prefer Adherence 14:1137\u20131144. https:\/\/doi.org\/10.2147\/PPA.S248584","journal-title":"Patient Prefer Adherence"},{"key":"5223_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43:3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"key":"5223_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40264-023-01346-9","volume":"46","author":"B Micallef","year":"2023","unstructured":"Micallef B, Dogn\u00e9 JM, Sultana J et al (2023) An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilance. Drug Saf 46:1089\u20131103. https:\/\/doi.org\/10.1007\/s40264-023-01346-9","journal-title":"Drug Saf"},{"key":"5223_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J (2023) Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep 13:18817. https:\/\/doi.org\/10.1038\/s41598-023-46275-w","journal-title":"Sci Rep"},{"key":"5223_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","volume":"38","author":"AC Pacurariu","year":"2015","unstructured":"Pacurariu AC, Straus SM, Trifir\u00f2 G et al (2015) Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf 38:1201\u20131210. https:\/\/doi.org\/10.1007\/s40264-015-0341-5","journal-title":"Drug Saf"},{"key":"5223_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21109\/kesmas.v15i2.3929","volume":"15","author":"R Pinzon","year":"2020","unstructured":"Pinzon R, Paramitha D, Wijaya VO (2020) Acceleration of telemedicine use for chronic neurological disease patients during COVID-19 pandemic in Yogyakarta, Indonesia: a case series study. Kesmas 15:28\u201331. https:\/\/doi.org\/10.21109\/kesmas.v15i2.3929","journal-title":"Kesmas"},{"key":"5223_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","volume":"118","author":"E Potter","year":"2025","unstructured":"Potter E, Reyes M, Naples J, Dal Pan G (2025) FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther 118:567\u2013582. https:\/\/doi.org\/10.1002\/cpt.3701","journal-title":"Clin Pharmacol Ther"},{"key":"5223_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0804","volume":"2","author":"W Rief","year":"2021","unstructured":"Rief W (2021) Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group. JAMA Health Forum 2:e210804. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.0804","journal-title":"JAMA Health Forum"},{"key":"5223_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5223_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40744-017-0080-4","volume":"4","author":"M Schiff","year":"2017","unstructured":"Schiff M, Saunderson S, Mountian I, Hartley P (2017) Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther 4:445\u2013463. https:\/\/doi.org\/10.1007\/s40744-017-0080-4","journal-title":"Rheumatol Ther"},{"key":"5223_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14712598.2022.2072207","volume":"22","author":"JM Serra L\u00f3pez-Matencio","year":"2022","unstructured":"Serra L\u00f3pez-Matencio JM, Gago-Veiga AB, G\u00f3mez M et al (2022) Treatment of migraine with monoclonal antibodies. Expert Opin Biol Ther 22:707\u2013716. https:\/\/doi.org\/10.1080\/14712598.2022.2072207","journal-title":"Expert Opin Biol Ther"},{"key":"5223_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.pop.2022.04.002","volume":"49","author":"J Shaver","year":"2022","unstructured":"Shaver J (2022) The state of telehealth before and after the COVID-19 pandemic. Prim Care 49:517\u2013530. https:\/\/doi.org\/10.1016\/j.pop.2022.04.002","journal-title":"Prim Care"},{"key":"5223_CR30","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2147\/PPA.S170636","volume":"12","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Sides R, Lanteri-Minet M et al (2018) Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence 12:1785\u20131795. https:\/\/doi.org\/10.2147\/PPA.S170636","journal-title":"Patient Prefer Adherence"},{"key":"5223_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2024","unstructured":"Sun W, Li Y, Xia B et al (2024) Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 14:1257282. https:\/\/doi.org\/10.3389\/fphar.2023.1257282","journal-title":"Front Pharmacol"},{"key":"5223_CR32","doi-asserted-by":"publisher","unstructured":"Tsuchiya M, Sakai T, Okada N et al (2025) Changes in the trend and quality of adverse drug reaction reports in the Japanese Adverse Drug Event Report database and the impact of COVID-19-related reports. Int J Pharm Pract: riaf084. https:\/\/doi.org\/10.1093\/ijpp\/riaf084","DOI":"10.1093\/ijpp\/riaf084"},{"key":"5223_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2025.1644680","volume":"5","author":"F van Hunsel","year":"2025","unstructured":"van Hunsel F, Kant A (2025) A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic. Front Drug Saf Regul 5:1644680. https:\/\/doi.org\/10.3389\/fdsfr.2025.1644680","journal-title":"Front Drug Saf Regul"},{"key":"5223_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.edurev.2020.100330","volume":"30","author":"J Vlasblom","year":"2020","unstructured":"Vlasblom J, Pennings H, van der Pal J, Oprins E (2020) Competence retention in safety-critical professions: a systematic literature review. Educ Res Rev 30:100330. https:\/\/doi.org\/10.1016\/j.edurev.2020.100330","journal-title":"Educ Res Rev"},{"key":"5223_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","volume":"33","author":"HW Wang","year":"2010","unstructured":"Wang HW, Hochberg AM, Pearson RK, Hauben M (2010) An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf 33:1117\u20131133. https:\/\/doi.org\/10.2165\/11584390-000000000-00000","journal-title":"Drug Saf"},{"key":"5223_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1693090","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Ke W, Li H (2025) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod. Front Pharmacol 16:1693090. https:\/\/doi.org\/10.3389\/fphar.2025.1693090","journal-title":"Front Pharmacol"},{"key":"5223_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1622736","volume":"16","author":"Y Xie","year":"2025","unstructured":"Xie Y, Li Q, Zhou J, Qin X, Zhang Z, Bai R (2025) Drug-induced Sweet\u2019s syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression. Front Immunol 16:1622736. https:\/\/doi.org\/10.3389\/fimmu.2025.1622736","journal-title":"Front Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05223-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05223-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05223-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:41Z","timestamp":1783907081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05223-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5223"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05223-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent and Institutional Review Board (IRB) approval were not required for this study. This research was a retrospective analysis of fully de-identified, publicly accessible data from the FDA Adverse Event Reporting System (FAERS). The dataset contains no personally identifiable information, eliminating the need for patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}